Hadassah

BioLineRx to Commence Phase 1 Stem Cell Trial at Hadassah Medical Organization

Thursday, Jun 19 2014

BioLineRx Ltd. has received approval from the Israeli Ministry of Health to commence a Phase 1 trial for BL-8040, a novel treatment for mobilizing stem cells from the bone marrow for treating acute myeloid leukemia, as well as other hematological malignancies. The study is expected to begin during the third quarter of 2014 at the Hadassah Medical Organization.

Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx, explains that stem cell mobilization is being used more and more as a method of collecting stem cells, instead of the traditional surgical procedure of bone marrow harvesting. Current treatment regimens, she notes, involve daily injections of G-CSF, a growth factor that stimulates the bone marrow to make white blood cells.

These injections are given for 4-6 days with or without the addition of a mobilizing agent such as Plerixafor (Mozobil). A previous Phase 1/2 study in multiple myeloma patients revealed that BL-8040 given as a single injection in combination with G-CSF injections was highly effective in mobilizing stem cells. The current trial aims to evaluate the mobilization capacity of one or two injections of BL-8040 as a stand-alone therapy, which could significantly shorten treatment and reduce costs.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Jul 19 2018

Hadassah Doctors in Forefront of Diabetes Prevention and Treatment

“Diabetes is on track to become the largest epidemic in human history.” So says Dr. Gil Leibowitz, incoming head of the Hadasah Diabetes Center at Hadassah Hospital Ein Kerem, and himself a diabetic since the age of seven.

READ MORE ›
alt_text

Wednesday, Jul 11 2018

Improving Kidney Health of Premature Babies

Is the TV hit show Grey's Anatomy taking its inspiration from Hadassah Hospital? After all, cast members did visit Hadassah Ein Kerem in 2011. Dr. Oded Volovelsky, Head of Hadassah's new Pediatric Nephrology Unit says, only half-jokingly, that TV doc Meredith Grey might have read his research.

READ MORE ›
alt_text

Wednesday, Jul 11 2018

Hadassah Cancer Specialists Explore Link Between Colorectal Cancer and BRCA Mutations

Looking further into the link between colorectal cancer and BRCA 1 and 2 genetic mutations, researchers from the Hadassah Medical Center’s Sharett Institute of Oncology, together with colleagues from Chaim Sheba Medical Center, analyzed data from 32 patients with lower gastrointestinal cancers.

READ MORE ›
alt_text

Monday, Jul 9 2018

World Hepatitis Day: Hadassah’s Contribution to the Global Battle Against this Disease

“Hadassah Medical Organization's (HMO) greatest contribution to the global battle against Hepatitis are the vaccines that have been developed here,” said Prof. Daniel Shouval, as we mark World Hepatitis Day on July 28.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More